Who is the CEO of Appili Therapeutics Inc.?

Dr. Donald D. Cilla Jr., M.B.A., Pharmd is a business executive who currently serves as the CEO of Appili Therapeutics Inc..

What is the Revenue Growth of Appili Therapeutics Inc.?

Revenue growth data for Appili Therapeutics Inc. is currently unavailable.

What is Appili Therapeutics Inc. operating Margin?

Appili Therapeutics Inc. operating margin is -4035.00% which shows how much profit APLIF earns from each dollar of sales, after subtracting the direct costs tied to generating that revenue.

In which market sector does Appili Therapeutics Inc. operate?

Sector information for Appili Therapeutics Inc. is currently unavailable.

What is Appili Therapeutics Inc. revenue growth?

Revenue growth data for Appili Therapeutics Inc. is currently unavailable.

Appili Therapeutics Inc.

APLIF•PNK

$0.01

$-0.01(-40.00%)

Appili Therapeutics Inc. (APLIF) Stock Overview

Explore Appili Therapeutics Inc.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for APLIFStats details for APLIF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations data is not available for APLIFAnalyst Recommendations details for APLIF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.

CEO

Dr. Donald D. Cilla Jr., M.B.A., Pharmd

Employees

Headquarters

#21-1344 Summer Street, Halifax, NS

Founded

2021